Clinical Trial: NCT06852638
CD70-targeted immunoPET Imaging of Malignant Cancers
Status:
RECRUITINGPhase:
Phase 2| Lead Sponsor: | RenJi Hospital |
| Information Provided By: | RenJi Hospital |
| Last Update Posted: | 2026-05-12 |
Study Overview
Brief Summary
This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.
Official Title
CD70-targeted PET/ CT in the Diagnosis of Malignant Cancers
Conditions
Renal Cancer, Renal Clear Cell Carcinoma, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma, Mantle Cell Lymphoma, Nasopharyngeal Carcinoma
Intervention / Treatment
- Drug: [18F]F-RESCA-RCCB6
- Drug: [18F]F-RESCA-R8B4
- Drug: [68Ga]Ga-NOTA-R8B4
- Drug: [18F]F-RESCA-RD06
- Drug: [68Ga]Ga-NOTA-RD06
Other Study ID Numbers
- LY2024-306-A
Start Date (Actual)
2024-12-23
Primary Completion Date (Estimated)
2026-12-23
Study Completion Date (Estimated)
2026-12-23
Enrollment (Estimated)
300
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | RenJi Hospital |
| Information Provided By: | RenJi Hospital |
| Last Update Posted: | 2026-05-12 |
Study Overview
Brief Summary
This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.
Official Title
CD70-targeted PET/ CT in the Diagnosis of Malignant Cancers
Conditions
Renal Cancer, Renal Clear Cell Carcinoma, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma, Mantle Cell Lymphoma, Nasopharyngeal Carcinoma
Intervention / Treatment
- Drug: [18F]F-RESCA-RCCB6
- Drug: [18F]F-RESCA-R8B4
- Drug: [68Ga]Ga-NOTA-R8B4
- Drug: [18F]F-RESCA-RD06
- Drug: [68Ga]Ga-NOTA-RD06
Other Study ID Numbers
- LY2024-306-A
Start Date (Actual)
2024-12-23
Primary Completion Date (Estimated)
2026-12-23
Study Completion Date (Estimated)
2026-12-23
Enrollment (Estimated)
300
Study Type
Interventional
Phase
Phase 2